Hidradentis Suppurativa | Treatment Algorithms: Claims Data Analysis | US | 2019
Following approval by the FDA in 2015, AbbVie’s Humira (adalimumab) became (and remains) the only approved therapy for the treatment of hidradenitis suppurativa. Humira is approved specifically for moderate to severe disease, and depending on their specific symptoms, patients may initially receive treatment with other off-label agents such as NSAIDs, antibiotics, and/or corticosteroids. Alternative biologics may also be used off-label in patients with more-severe disease and who do not respond to Humira (e.g., Janssen’s Remicade [infliximab]). This content will provide manufacturers of current treatments, as well as those developing novel hidradenitis suppurativa agents, with insights regarding the use of hidradenitis suppurativa drugs and will add a perspective of market trends in the hidradenitis suppurativa space.
What patient shares do key therapies and brands garner by line of therapy in newly diagnosed hidradenitis suppurativa patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed hidradenitis suppurativa patients?
How has AbbVie’s Humira been integrated into the treatment algorithm, and what is its source of business?
What percentage of patients receive drug therapy within 365 days of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within 365 days of diagnosis?
What percentage of patients are treated with monotherapy vs. combination therapy? What are the most commonly used combinations?
What are the product-level compliance and persistency rates among drug-treated patients?
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.